stockrowVaxcyte, Inc.
PCVX Healthcare Biotechnology
- EPS
- −61.5%
- Free cash flow
- −92.6%
Quarter to June 2026, against a year earlier
Follow PCVX
Alert me
Vaxcyte, Inc. (PCVX) Return on equity
Vaxcyte, Inc.'s return on equity over the twelve months to 30 June 2026 was −36.5%, down 10.9 percentage points from fiscal 2025 (−25.6%). Over the past ten years it has ranged from −74.5% (fiscal 2020) to 61.3% (fiscal 2019); the current reading is higher than 63% of that period. That is above the Biotechnology industry median of −50.1% and below the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −25.6% | (5.18) |
| FY2024 | −20.4% | 16.26 |
| FY2023 | −36.7% | (0.56) |
| FY2022 | −36.1% | (4.33) |
| FY2021 | −31.8% | 42.73 |
| FY2020 | −74.5% | (135.78) |
| FY2019 | 61.3% | 25.33 |
| FY2018 | 35.9% | — |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| IBRX ImmunityBio, Inc. compare | 122.9% |
| TGTX TG Therapeutics, Inc. compare | 100.3% |
| PTGX Protagonist Therapeutics, Inc. compare | 11.0% |
| TECH Bio-Techne Corp compare | 9.03% |
| CAI Caris Life Sciences,�Inc. compare | 0.00% |
| BMRN BioMarin Pharmaceutical Inc. compare | −0.31% |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −24.8% |
| TWST Twist Bioscience Corporation compare | −29.6% |
| PCVX Vaxcyte, Inc. | −36.5% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)